Roche launches cobas pure integrated solutions analyser with 230 tests across disease areas

• With a footprint of just two square meters, cobas pure provides clinical labs with access to more than 230 diagnostic tests across a wide range of disease areas including infectious diseases, oncology, and cardiology.

• Plastic generated per test result has been reduced by up to 78% due to the smaller size of the reagent package while offering more testing per package.

• Is seamlessly compatible with cobas infinity laboratory solution, browser-based software that bridges pre-analytics, analytics, and post-analytics while driving intelligent sample processing and auto-validation for efficient result management.

  ---

Mumbai: Roche Diagnostics India has launched cobas pure integrated solutions analyzer with a more intelligent system particularly suitable for a large number of labs and hospitals operating in India. As per the company, it helps make better use of space and expand offering of high medical value tests for the benefit of patients.

This new compact analyzer combines clinical chemistry, immunoassay, and Ion Concentration Measurement (ISE) diagnostic testing on a single platform helping labs simplify daily operations with limited space and resources. Cobas pure analyzer offers the longest onboard stability of reagents allowing labs to expand their test menu.

Built on the latest technology, cobas pure integrated solutions analyzer provides labs with an integrated system that focuses on the automation of manual tasks. This reduces the hands-on maintenance time of technicians to just 5 minutes per day which is 80 percent less than previous generation systems. This will help improve the productivity of lab personnel whilst also enabling faster delivery of test results and clinical decision-making.

With a footprint of just two square meters, cobas pure analyzer is smaller than previous generation systems. It is able to perform up to 870 tests per hour whilst providing medium-sized labs with access to the full clinical chemistry and immunochemistry assay menu from Roche which includes more than 230 diagnostic tests across a wide range of disease areas such as critical care, infectious diseases including COVID-19, Women’s Health, Oncology, Cardiology, Endocrinology and TDM (Therapeutic Drug Monitoring).

Announcing the launch, Narendra Varde, Managing Director, Roche Diagnostic India, and Neighboring Markets said, “Cobas pure offers diverse critical and complex tests for patients. This consolidation of the test menu would enable labs to speedily perform hundreds of different tests using just a single test tube of the blood samples from patients. Through cobas pure, the consolidated test menu can reach beyond metros into a large number of cities where testing menu may be presently limited.”

Furthermore, to ensure simple and effective coordination across healthcare networks, Cobas pure integrated solutions provide fully standardized results and operational compatibility with Cobas pro integrated solutions – Roche’s latest analyzer designed for larger labs. Cobas pure integrated solutions analyzer is also fully compatible with the cobas infinity laboratory solution, a software solution designed to optimize information processing from ordering to result management, while intelligently automating the entire sample flow from receipt to storage and bringing meaningful insights for informed decision making.

Cobas pure integrated solutions come with a number of innovations including automated maintenance and calibration and completely ready to use reagents that help simplify overall lab operations.

In line with Roche’s continuous focus on driving sustainable practices across business practices and offerings, the plastic generated per test result has been reduced by up to 78% due to smaller reagent pack sizes with the higher number of tests per pack. ii, iii Roche has been recognized for the twelfth consecutive year, as one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices (DJSI).

Also, the required sample volume per test has been reduced on average by 43% compared to previous generation cobas systems.